DeFronzo RA - Search Results

1

Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial.

Rasouli N, Younes N, Ghosh A, Albu J, Cohen RM, DeFronzo RA, Diaz E, Sayyed Kassem L, Luchsinger JA, McGill JB, Sivitz WI, Tamborlane WV, Utzschneider KM, Kahn SE; GRADE Research Group. Rasouli N, et al. Among authors: defronzo ra. Diabetes Care. 2024 Apr 1;47(4):580-588. doi: 10.2337/dc23-1070. Diabetes Care. 2024. PMID: 38211595 Clinical Trial.

2

Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes.

Pratipanawatr T, Cusi K, Ngo P, Pratipanawatr W, Mandarino LJ, DeFronzo RA. Pratipanawatr T, et al. Among authors: defronzo ra. Diabetes. 2002 Feb;51(2):462-8. doi: 10.2337/diabetes.51.2.462. Diabetes. 2002. PMID: 11812756

3

Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.

Miyazaki Y, Matsuda M, DeFronzo RA. Miyazaki Y, et al. Among authors: defronzo ra. Diabetes Care. 2002 Mar;25(3):517-23. doi: 10.2337/diacare.25.3.517. Diabetes Care. 2002. PMID: 11874940 Clinical Trial.

4

Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus.

Miyazaki Y, Glass L, Triplitt C, Wajcberg E, Mandarino LJ, DeFronzo RA. Miyazaki Y, et al. Among authors: defronzo ra. Am J Physiol Endocrinol Metab. 2002 Dec;283(6):E1135-43. doi: 10.1152/ajpendo.0327.2001. Am J Physiol Endocrinol Metab. 2002. PMID: 12424102 Free article. Clinical Trial.

5

Analysis of metabolic parameters as predictors of risk in the RENAAL study.

Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, Burgess E, Hille DA, Dickson TZ, Shahinfar S, Brenner BM; RENAAL Study. Appel GB, et al. Among authors: defronzo ra. Diabetes Care. 2003 May;26(5):1402-7. doi: 10.2337/diacare.26.5.1402. Diabetes Care. 2003. PMID: 12716796

6

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.

Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA. Bajaj M, et al. Among authors: defronzo ra. Diabetes. 2003 Jun;52(6):1364-70. doi: 10.2337/diabetes.52.6.1364. Diabetes. 2003. PMID: 12765945

7

Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.

Miyazaki Y, He H, Mandarino LJ, DeFronzo RA. Miyazaki Y, et al. Among authors: defronzo ra. Diabetes. 2003 Aug;52(8):1943-50. doi: 10.2337/diabetes.52.8.1943. Diabetes. 2003. PMID: 12882909 Clinical Trial.

8

Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects.

Wajcberg E, Miyazaki Y, Triplitt C, Cersosimo E, DeFronzo RA. Wajcberg E, et al. Among authors: defronzo ra. Diabetes Care. 2004 Dec;27(12):2868-73. doi: 10.2337/diacare.27.12.2868. Diabetes Care. 2004. PMID: 15562199 Clinical Trial.

9

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. DeFronzo RA, et al. Diabetes Care. 2005 May;28(5):1092-100. doi: 10.2337/diacare.28.5.1092. Diabetes Care. 2005. PMID: 15855572 Clinical Trial.

10

Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial.

DeFronzo RA, Bergenstal RM, Cefalu WT, Pullman J, Lerman S, Bode BW, Phillips LS; Exubera Phase III Study Group. DeFronzo RA, et al. Diabetes Care. 2005 Aug;28(8):1922-8. doi: 10.2337/diacare.28.8.1922. Diabetes Care. 2005. PMID: 16043733 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

669 results

Search Page